--- title: "Citius Oncology (CTOR.US) — Financial Reports" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/CTOR.US/norm.md" symbol: "CTOR.US" name: "Citius Oncology" parent: "https://longbridge.com/en/quote/CTOR.US.md" datetime: "2026-05-21T18:32:24.066Z" locales: - [en](https://longbridge.com/en/quote/CTOR.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/CTOR.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/CTOR.US/norm.md) --- # Citius Oncology (CTOR.US) — Financial Reports ## Income Statement (USD) | Indicator | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | | --- | --- | --- | --- | --- | --- | | EPS | -0.2700 | -0.0633 | -0.0637 | -0.0750 | -0.1081 | | ROE | -227.23% | -42.87% | -51.74% | -63.14% | -80.44% | | Revenue | 1.67M | 3.94M | - | - | - | | Net income | -26.61M | -5.53M | -5.00M | -5.37M | -7.74M | | Operating income | -28.61M | -5.25M | -4.71M | -4.94M | -7.47M | | Gross margin | 80.27% | 79.99% | - | - | - | | Net margin | -1595.98% | -140.31% | - | - | - | | Profit quality | - | - | - | - | - | ## Balance Sheet (USD) | Indicator | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | | --- | --- | --- | --- | --- | --- | | A&L | 100.70M | 109.97M | 100.94M | 91.71M | 91.44M | | Leverage | 2.86 | 1.88 | 2.25 | 2.83 | 2.57 | | BVPS | 0.3793 | 0.6889 | 0.5372 | 0.4528 | 0.4981 | | Turnover | 0.0584 | 0.0394 | - | - | - | | Cash & STI | 2.63M | 7.30M | 3.92M | 112.00 | 112.00 | | Inv & Rec | 22.66M | 22.64M | 22.29M | 17.21M | 15.34M | | LT assets | - | - | - | - | - | | Net debt | 1.17M | -3.50M | -124797.00 | 3.80M | 3.80M | ## Cash Flow Statement (USD) | Indicator | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | | --- | --- | --- | --- | --- | --- | | Operating CF | -3.83M | -7.35M | -5.49M | 0.0000 | 0.0000 | | Investing CF | -600000.00 | -4.40M | -5.75M | - | - | | Financing CF | -231199.00 | 15.13M | 15.17M | - | - | | Free CF | 3.93M | -14.17M | -15.20M | 2.02M | 2.80M | | OCF coverage | - | - | - | - | - | | Repaid & issued | - | - | - | - | - | | CapEx | - | - | - | - | - |